
Weill Cornell Medicine Meyer Cancer Center

Background and Solution

At the Weill Cornell Medicine Meyer Cancer Center Cancer Clinical Trials Office (MCC CCTO), paper adverse event (AE) logs were used for collection, and investigator grading and attribution of AEs. This workflow resulted in missing data and long review/sign-off times. To streamline procedures and improve AE review times, with a goal of 5 days to review, the CCTO piloted the

Original Workflow



Alexander Toth; Roman Savrasov MD; Sabrina Guervil MHA; Brittany Hobbie MPH; Anita Ou MPH, CCRP; Peter Martin MD

Improvement in Adverse Event Review Times: Piloting the Epic Adverse Event Module and New AE Collection Workflows

Methods

- 1) Forty three AEs reviewed using Paper and 39 AEs reviewed using Epic were identified.
- 2) Date each AE was reported and date of investigator review were collected.
- 3) Difference in the number of days between the AEs report date and Investigator review date were calculated.
- 4) Mean Days to Review was calculated for both Paper and Epic.



The new AE workflow and use of the Epic AE module decreased review timelines. Despite the reduction, AEs were not reviewed within the targeted 5 day timeline. Further evaluation of research coordinator and investigator timelines will help identify bottle necks and direct education and oversight to help bring review of AEs closer to the 5-day goal. It was unclear how much improvement in timelines was due to establishing expectations and moving the workflow into clinic versus being due to using the electronic Epic system instead of paper. The MCC CCTO plans to roll out the new AE capture workflow and use of the Epic AE module across all research teams. An analysis following the broad roll out is planned to measure the impact of the

Epic AE Module Example										
ead-only.		I								?
ne advers	e events for this study. Clinically Significant	Expected	Start Date	Resolved	Outcomes	Actions Taken	Grade	Attribution	Updated	
ło	No	No	1/19/2023	3/15/2024	Resolved without Sequelae	None	Current Grade	Study Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) P1090 POLATUZUMAB VEDOTIN IN 100 ML IVPB Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) riTUXimab-abbs (TRUXIMA) Solution Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) P1444 RITUXIMAB-ABBS (TRUXIMA) IVPB 2 MG/ML SLOW INFUSION Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) P1444 RITUXIMAB-ABBS (TRUXIMA) IVPB 2 MG/ML STANDARD INFUSION Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) P1444 RITUXIMAB-ABBS (TRUXIMA) IVPB 2 MG/ML STANDARD INFUSION Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) P1444 RITUXIMAB-ABBS (TRUXIMA) IVPB 250 ML RAPID INFUSION Attribution Unrelated Unlikely	3/31/2024 Terrest A	
SERD is	improved with Nexium (orade 1)						Definite		
No	No	No	9/1/2023	10/17/2023	Resolved without Sequelae	None	Current Grade012345	Study Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) P1090 POLATUZUMAB VEDOTIN IN 100	2/7/2024 MD	
								ML IVPB Attribution Unrelated Unlikely Possible Probable Definite INV (ST3) riTUXimab-abbs (TRUXIMA) Solution		
								Attribution Unrelated Unlikely Possible Probable		

Lessons Learned and Future Directions

Acknowledgements

Thank you to the CCTO Lymphoma Research Team who was first to pilot the new AE workflow.